22.97USD-0.39%Mkt Cap: 2.99B USDP/E: —Last update: 2026-06-01
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pi…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.99B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-148.96M USD
Revenue/Share—
Last Price22.97 USD
Fiscal Year EndDec 2025
MR Quarter—
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.15
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-1.78
EPS (Forward)-3.73
52W Range
19.0143% of range28.23
52W High28.23 USD
52W Low19.01 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE41.79%
ROA-21.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.21M USD
CapEx (TTM)2.09M USD
FCF Margin—
FCF Yield-2.00%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.03
Current Ratio12.02
Quick Ratio11.83
Book Value/Sh-18713.6720 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)42.60 USD
Target Range30.00 USD – 57.00 USD
# Analysts5
Ownership
Shares Out.129.57M
Float8.66K
Insiders0.00%
Institutions39.78%
Short Interest
Short Ratio2.3d
Short % Float2.05%
Short % Out.2.05%
Shares Short1.95M
Technical
SMA 5022.92 (+0.2%)
SMA 20022.92 (+0.2%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)642.35K
Avg Vol (10d)407.15K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—